Pediatric Hematology/Oncology
Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.
Recent Discussions
Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?
COVID-19 disease in children seems to be less severe than adults based on the current literature and our personal experience at Children's Hospitals. Among adults, the coagulopathy is beginning to be described with elevated inflammatory markers and other markers of coagulation activation, including ...
For transplant-ineligible aplastic anemia planned for immunosuppression, how do you approach duration and tapering of cyclosporine and eltrombopag?
One of the most common mistakes in the management of AA is premature tapering of cyclosporine or tacrolimus. If there is a complete remission, and by that I mean normalization of counts, not complete remission as defined in some papers (e.g., ANC 1000, Plts 100,000, Hb 10 as in de Latour et al., PMI...
Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?
Germ Cell Tumor Management in face of SARS-CoV-2: Safe, Rational Modifications to Standard GCT Practice to Protect Public Health, GCT Outcomes, GCT Patients, and Health Systems. This bulletin has been produced by a concerned group of international experts in germ cell tumors, has not undergone exten...
How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?
It was very exciting to see PARADIGM presented as a plenary at ASH, and I look forward to the manuscript! Interpreting the findings in the context of the enrolled patients is very important. The median age of enrolled patients was approximately 65 years in both arms, and ~75% of enrolled patients ha...
When would you use dexamethasone-free antiemetic prophylaxis with olanzapine in pediatric patients receiving highly emetogenic chemotherapy?
At our institution, our leukemia/lymphoma, bone marrow transplant, and neuro-oncology providers generally do not feel comfortable with the use of dexamethasone for the prevention of CINV in their patients. In addition, neuroblastoma patients receiving dinutuximab also do not receive dexamethasone. T...
How would you approach adjuvant radiation therapy for a young adult woman with recurrent myxopapillary ependymoma?
Extraneural spread of a myxopapillary ependymoma is exceptionally rare. In this case, I would strongly favor adjuvant local radiotherapy to the postoperative sites, assuming they have not previously received prohibitive radiation doses (especially the pre-coccygeal site). The situation is different ...
How do you explain the use of an AI scribe to patients the first time it is used in their care?
I use an AI scribe in my outpatient clinic, and around 90–95% of my patients agree to it. I obtain consent at the start of each visit and make it clear that it's completely optional—that they can say no at the start or change their mind at any point in the visit, with no impact on their care. I also...
What is your approach to iron supplementation in patients with an active infection?
In patients with active infections, I generally avoid intravenous iron due to the potential for promoting pathogen growth, a practice supported by cautions from nephrology and gastroenterology society guidelines. However, evidence for the risk of infection with IV iron is inconsistent, underpowered,...
How would you manage a patient with HbSS and severe pulmonary hypertension on home oxygen?
This patient should be referred to a specialist in pulmonary hypertension in sickle cell disease for right heart catheterization and aggressive management of the pulmonary hypertension. As described, the patient is not a good candidate for lung transplant or gene therapy.
Between the MERLIN and CASTLE tests for melanoma, which do you prefer and why?
I prefer DecisionDx-Melanoma, without question. It’s the only test that prospectively met its primary endpoint, with SLN positivity below 5% in the low-risk group. Merlin’s CP-GEP did not meet that threshold in MERLIN_001. DecisionDx also goes beyond the SLNB decision by independently predicting rec...